Navigation Links
Jennerex Appoints James M. Burke, M.D. Vice President, Clinical Research
Date:2/22/2011

SAN FRANCISCO, Feb. 22, 2011 /PRNewswire/ -- Jennerex, Inc. (San Francisco), a clinical-stage cancer biotherapeutics company, today announced the appointment of James M. Burke, M.D. to the newly-created position of vice president, clinical research. Dr. Burke will be responsible for all global clinical research activities related to Jennerex pipeline compounds.

"Dr. Burke has been working with Jennerex in an advisory capacity as a clinical advisor for over a year, and has provided significant contributions to the strategic direction and clinical development of JX-594 for the treatment of liver cancer, and we look forward to bringing his expertise in-house," said David H. Kirn, M.D., president and chief executive officer of Jennerex. "In addition, as we advance our earlier stage pipeline products, Dr. Burke's direct clinical research experience using immunotherapeutics to treat multiple solid tumors will be instrumental as we pursue continued development of JX-929, JX-1395 and our next generation products."

Dr. Burke brings approximately 20 years of experience in basic and applied clinical science of genetic and immunotherapy.  His clinical research using immunotherapeutics including oncolytic viruses for the treatment of various cancers have advanced the understanding of the medical applications for oncolytic virus therapy. Prior to Jennerex, Dr. Burke was the Director of Cancer Research at Billings Clinic, where he was also a clinical investigator for JX-594. He had previously served as associate director of clinical research at Cell Genesys, Inc., where he was responsible for the development of the oncolytic adenovirus platform of agents and other gene therapy vaccines for the treatment of cancer and other diseases.  In addition, after completing his Hematology and Oncology Fellowship at UC San Francisco (UCSF), he was an attending physician at UCSF in the department of hematology and oncology. He received his M.D. from Georgeto
'/>"/>

SOURCE Jennerex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Jennerex and Transgene Enter Into an Exclusive Partnership for the Development and Commercialization of JX-594 for the Treatment of Cancers
2. Jennerex Completes Fully Subscribed Private Placement for Aggregate Gross Proceeds of $8.6 Million
3. Jennerex Reports Positive Phase 1 Results for JX-594 Administered Intravenously
4. Jennerex Adds Industry Veteran Paul Cleveland to Board of Directors
5. Jennerex Completes Over-Subscribed Series C Financing for Aggregate Gross Proceeds of Over $5.5 Million
6. Jennerex Closes $5 Million First Tranche of Series C Financing
7. Nature Reviews Publishes Article About Jennerexs Multi-Mechanistic Cancer Therapeutic
8. Jennerex Appoints Samantha Miller as Vice President of Corporate Development
9. Jennerex Completes $8.3 Million Series B Financing and Appoints Dr. Cal Stiller as Director
10. ALS Therapy Development Institute Appoints Anil Godhwani to Board of Directors
11. Amarin Corporation Appoints Industry Veteran Paul E. Huff as Chief Commercial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Pittsburgh, PA (PRWEB) January 15, 2014 The ... Company, publisher of Food Safety Tech , an e-Journal ... has signed an agreement for the second year for the ... with Pittcon 2014. The partnership provides that the registration fee ...
(Date:1/15/2014)... Westlake Village, Calif. (PRWEB) January 15, 2014 ... cancer treatment and management through the genomic analysis of ... will offer Therapy Finder™, a web-based cancer decision support ... a reporting option with Cynvenio’s ClearID™ genomic test, Therapy ...
(Date:1/15/2014)... Canada (PRWEB) January 15, 2014 This ... on nonclinical and clinical safety assessment in biosimilars. , ... path for biosimilar drug development, however the complex nature ... to quality, safety and efficacy extremely challenging. Based on ...
(Date:1/15/2014)... Reston, VA (PRWEB) January 15, 2014 ... education have continued their sponsorship of an annual competition ... interest in, and access to, innovative STEM study. The ... , TEAMS: Tests of Engineering Aptitude, Mathematics, and ...
Breaking Biology Technology:Pittcon Announces Second Year Partnership With Food Safety Tech 2Pittcon Announces Second Year Partnership With Food Safety Tech 3Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5
... a regulatory framework to guide the approval of the ... providing more affordable treatment for millions of Americans suffering ... chairman and CEO of Medco Health Solutions, Inc. (NYSE: ... and innovation over a period of many years has ...
... CASTLE, Del., March 12 -- Arkion(R) Life Sciences has ... AV-1011 Liquid Rice Seed Treatment in Louisiana and Missouri ... The EPA approval means that rice growers in these ... grackles. The new bird repellent effectively stops birds ...
... States, long the beneficiary of talented immigrants, must act ... pursue expanding opportunities in their home countries, according to ... Science and Technology .In A Reverse Brain Drain ... Harvard Law School, writes that immigrant scientists and engineers, ...
Cached Biology Technology:Biogenerics Legislation Provides Critical Pathway to Affordable Access for Patients with Chronic and Complex Conditions 2Biogenerics Legislation Provides Critical Pathway to Affordable Access for Patients with Chronic and Complex Conditions 3AV-1011 Bird Repellent to Protect Rice Seed Approved for Use in Louisiana and Missouri 2U.S. Risks Losing Highly Skilled Immigrants 2U.S. Risks Losing Highly Skilled Immigrants 3
(Date:4/23/2014)... announced Sophie Martin of the University of Lausanne, Switzerland, ... The award acknowledges her work to understand the molecular ... cell. , Martin has been working for the past ... way in which the spatial organization of cells contributes ... 11 years, she has been using fission yeast, which ...
(Date:4/23/2014)... new study by a University of Exeter researcher has ... of wild camels thriving in Australia,s remote outback have ... scale. , Sarah Crowley, of the Environment and Sustainability ... the history of the camel in Australia, from their ... to their current status as unwelcome "invader." , The ...
(Date:4/23/2014)... a technique used to read quickly. It involves ... non-essential words and/ or sentences. Similarly to humans, ... quickly "read" genetic information. Genes that need to ... smaller the encoding message, the easier it will ... Instituto Gulbenkian de Cincia (IGC, Portugal) and Centre ...
Breaking Biology News(10 mins):EMBO Gold Medal 2014 awarded to Sophie Martin 2How Australia got the hump with 1 million feral camels 2How Australia got the hump with 1 million feral camels 3Cell division speed influences gene architecture 2
... from North Carolina State University, the University of Washington ... most diverse collections of prehistoric non-native animal remains in ... find contributes to our understanding of culture in the ... may have been more important than previously thought. ...
... The Saint Louis Zoo,s Ron Goellner Center for ... on Nov. 30, 2011, that Ozark hellbenders have been ... subspecies of hellbender. This decade-long collaboration has yielded ... Nov. 15, and currently there are approximately 120 additional ...
... COPENHAGEN, DENMARK/ROCKVILLE, MD, USA Statens Serum Institut and Aeras ... trial of a new candidate TB vaccine designed to protect ... The trial is being conducted by the South African ... in the Western Cape province of South Africa. Dr. Hassan ...
Cached Biology News:Archaeologists find new evidence of animals being introduced to prehistoric Caribbean 2World's first captive breeding of Ozark hellbenders at Saint Louis Zoo 2World's first captive breeding of Ozark hellbenders at Saint Louis Zoo 3Vaccine targeting latent TB enters clinical testing 2
Sigmas E-TOXATE (Limulus Amebocyte Lysate) test kits are intended for the detection and semiquantitation of endotoxins for research purposes. sensitivity 0.05-0.1 EU/mL...
... The Label IT siRNA Tracker Intracellular Localization ... directly label and deliver siRNA, of your ... for in vitro tracking experiments. Subcellular localization ... can be monitored following introduction of the ...
... MW: 60kDa (A) and 36kDa (C) ... pH 7.5, 500mM NaCl, 60mM 2-mercaptoethanol, ... 1mM DTT, and 0.1mg/ml serum albumin ... of proteins. Purification: DEAE chromatography, aminohexyl-agarose ...
... The Label IT siRNA Tracker Intracellular ... to directly label and deliver siRNA, of ... manner, for in vitro tracking experiments. Subcellular ... expression can be monitored following introduction of ...
Biology Products: